Breaking News

Moderna Awarded $176M BARDA Contract for Avian Flu Vaccine

Will support late-stage development for an mRNA-based vaccine to enable the licensure of a vaccine against H5 influenza virus.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna, Inc. announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The project award will support late-stage development for an mRNA-based v...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters